Compare Nu Holdings Ltd (NU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Nu Holdings Ltd trades at $15.58 (market cap $74.30B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: Nu Holdings Ltd is far larger — about 7.3× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| NU | XBI | |
|---|---|---|
Market Cap | $74.30B | $10.11B |
Volume | 80,294,805 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $18.76 | $169.55 |
52-Week Low | $11.60 | $104.99 |
Typical Hold Time | 53 Days | 37 Days |
Enterprise Value | $96.91B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, with strong fundamental momentum despite recent volatility. The stock shows bullish technical signals with moving averages supporting upward trends, while oscillators indicate some near-term pressure. Revenue growth has accelerated from $3.0B in 2022 to $10.6B in 2025, with net income turning positive and reaching $2.9B. Recent news highlights acquisition speculation and Goldman Sachs' bullish stance, though the company denied Monzo deal talks.
The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target offering 6% upside. Key opportunities include expanding Latin American digital banking penetration and strong profitability metrics (27.4% net margin). Risks include credit quality concerns from rising delinquencies and competitive pressures in fintech. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
